Dermira (NASDAQ:DERM) is up 27% premarket on increased volume in apparent reaction to AnaptysBio’s etokimab flop in a mid-stage atopic dermatitis study.
Investors apparently believe the situation bodes well for the company’s lebrikizumab, an IL-13 inhibitor, in Phase 3 development for the same indication.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.